In conclusion, the current phase 1 study highlights the promising clinical efficacy of SY-5007 in both treatment-naïve and prior treated patients with advanced RET fusion-positive NSCLC, RET fusion-positive PTC and RET-mutant MTC. Here, RET is linked to non-small cell lung carcinoma.